<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32471232</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>CRISPR/Cas9-Mediated Gene Correction to Understand ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3801</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21113801</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the death of motor neurons in the spinal cord and brainstem. ALS has a diverse genetic origin; at least 20 genes have been shown to be related to ALS. Most familial and sporadic cases of ALS are caused by variants of the <i>SOD1</i>, <i>C9orf72,</i> <i>FUS</i>, and TARDBP genes. Genome editing using clustered regularly interspaced short palindromic repeats/CRISPR-associated system 9 (CRISPR/Cas9) can provide insights into the underlying genetics and pathophysiology of ALS. By correcting common mutations associated with ALS in animal models and patient-derived induced pluripotent stem cells (iPSCs), CRISPR/Cas9 has been used to verify the effects of ALS-associated mutations and observe phenotype differences between patient-derived and gene-corrected iPSCs. This technology has also been used to create mutations to investigate the pathophysiology of ALS. Here, we review recent studies that have used CRISPR/Cas9 to understand the genetic underpinnings of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Yeomin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Spine and Spinal Cord Institute, College of Medicine, Yonsei University, Seoul 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul 03722, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Yoon</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Spine and Spinal Cord Institute, College of Medicine, Yonsei University, Seoul 03722, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul 03722, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052416" MajorTopicYN="N">Targeted Gene Repair</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR/Cas9</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">gene correction</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells (iPSCs)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32471232</ArticleId><ArticleId IdType="pmc">PMC7312396</ArticleId><ArticleId IdType="doi">10.3390/ijms21113801</ArticleId><ArticleId IdType="pii">ijms21113801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24:S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Gendron T.F., Staff N.P. Amyotrophic lateral sclerosis: An update for 2018. Mayo Clin. Proc. 2018;93:1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in cu/zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R., Wai-Ling Butler A., Andersen P.M., Powell J.F., Al-Chalabi A. Alsod: The amyotrophic lateral sclerosis online database. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2008;9:249&#x2013;250. doi: 10.1080/17482960802146106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802146106</ArticleId><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., Veys K., Guo W., Sicart A., Vints K., Swijsen A., Moisse M., Eelen G., Gounko N.V., Fumagalli L., et al. Differentiation but not als mutations in fus rewires motor neuron metabolism. Nat. Commun. 2019;10:4147. doi: 10.1038/s41467-019-12099-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12099-4</ArticleId><ArticleId IdType="pmc">PMC6742665</ArticleId><ArticleId IdType="pubmed">31515480</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Edaravone: A new drug approved for als. Cell. 2017;171:725. doi: 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Appel S.H. Introduction to supplement: The current status of treatment for als. Amyotroph. Lateral Scler. Front. Degener. 2017;18:1&#x2013;4. doi: 10.1080/21678421.2017.1361447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361447</ArticleId><ArticleId IdType="pubmed">28872909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Als/riluzole study group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>You L., Tong R., Li M., Liu Y., Xue J., Lu Y. Advancements and obstacles of crispr-cas9 technology in translational research. Mol. Ther. Methods Clin. Dev. 2019;13:359&#x2013;370. doi: 10.1016/j.omtm.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2019.02.008</ArticleId><ArticleId IdType="pmc">PMC6447755</ArticleId><ArticleId IdType="pubmed">30989086</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeder M.L., Gersbach C.A. Genome-editing technologies for gene and cell therapy. Mol. Ther. J. Am. Soc. Gene Ther. 2016;24:430&#x2013;446. doi: 10.1038/mt.2016.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.10</ArticleId><ArticleId IdType="pmc">PMC4786923</ArticleId><ArticleId IdType="pubmed">26755333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Gersbach C.A., Barbas C.F., 3rd Zfn, talen, and crispr/cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397&#x2013;405. doi: 10.1016/j.tibtech.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2013.04.004</ArticleId><ArticleId IdType="pmc">PMC3694601</ArticleId><ArticleId IdType="pubmed">23664777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin A.M.G., Shadfar S., Vidal M., Jamali M.S., Atkin J.D. Motor neuron susceptibility in als/ftd. Front. Neurosci. 2019;13:532. doi: 10.3389/fnins.2019.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland J.M., Barohn R.J., McVey A.L., Katz J.S., Dimachkie M.M. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol. Clin. 2015;33:735&#x2013;748. doi: 10.1016/j.ncl.2015.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.006</ArticleId><ArticleId IdType="pmc">PMC4629510</ArticleId><ArticleId IdType="pubmed">26515618</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad L.I., Rouleau G.A., Ravits J., Cashman N.R. Clinical spectrum of amyotrophic lateral sclerosis (als) Cold Spring Harb. Perspect. Med. 2017;7:a024117. doi: 10.1101/cshperspect.a024117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024117</ArticleId><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Boum&#xe9;diene F., Logroscino G., Couratier P., Babron M.C., Leutenegger A.L., Copetti M., Preux P.M., Beghi E. Variation in worldwide incidence of amyotrophic lateral sclerosis: A meta-analysis. Int. J. Epidemiol. 2017;46:57&#x2013;74. doi: 10.1093/ije/dyw061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Kaye W., Raymond J., Wu R., Larson T., Punjani R., Heller D., Cohen J., Peters T., Muravov O., et al. Prevalence of amyotrophic lateral sclerosis&#x2014;United states, 2014. Mmwr. Morb. Mortal. Wkly. Rep. 2018;67:216&#x2013;218. doi: 10.15585/mmwr.mm6707a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6707a3</ArticleId><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Horton D.K., Kasarskis E.J., Tessaro E., Eisenberg M.S., Laird S., Iskander J. Cdc grand rounds: National amyotrophic lateral sclerosis (als) registry impact, challenges, and future directions. Mmwr. Morb. Mortal. Wkly. Rep. 2017;66:1379&#x2013;1382. doi: 10.15585/mmwr.mm6650a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6650a3</ArticleId><ArticleId IdType="pmc">PMC5751576</ArticleId><ArticleId IdType="pubmed">29267263</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Shatunov A., Jones A.R., Andersen P.M., Powell J.F., Al-Chalabi A. Development of a smartphone app for a genetics website: The amyotrophic lateral sclerosis online genetics database (alsod) Jmir Mhealth Uhealth. 2013;1:e18. doi: 10.2196/mhealth.2706.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/mhealth.2706</ArticleId><ArticleId IdType="pmc">PMC4114449</ArticleId><ArticleId IdType="pubmed">25098641</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. Alsod: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. Als genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarrott J.M., Herranz-Mart&#xed;n S., Alrafiah A.R., Shaw P.J., Azzouz M. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin. Biol. Ther. 2015;15:935&#x2013;947. doi: 10.1517/14712598.2015.1044894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2015.1044894</ArticleId><ArticleId IdType="pubmed">25959569</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Spek R.A.A., Van Rheenen W., Pulit S.L., Kenna K.P., Van den Berg L.H., Veldink J.H. The project mine databrowser: Bringing large-scale whole-genome sequencing in als to researchers and the public. Amyotroph. Lateral Scler. Front. Degener. 2019;20:432&#x2013;440. doi: 10.1080/21678421.2019.1606244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1606244</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheenen W.V., Pulit S.L., Dekker A.M., Khleifat A.A., Brands W.J., Iacoangeli A., Kenna K.P., Kooyman M., McLaughlin R.L., Middelkoop B., et al. Project mine: Study design and pilot analyses of a large-scale whole genome sequencing study in amyotrophic lateral sclerosis. J. bioRxiv. 2017:152553. doi: 10.1101/152553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/152553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X., Le W. Genetics of amyotrophic lateral sclerosis: An update. Mol. Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-28</ArticleId><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Charpentier E., Marraffini L.A. Harnessing crispr-cas9 immunity for genetic engineering. Curr. Opin. Microbiol. 2014;19:114&#x2013;119. doi: 10.1016/j.mib.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2014.07.001</ArticleId><ArticleId IdType="pmc">PMC4155128</ArticleId><ArticleId IdType="pubmed">25048165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hryhorowicz M., Lipi&#x144;ski D., Zeyland J., S&#x142;omski R. Crispr/cas9 immune system as a tool for genome engineering. Arch. Immunol. Et Ther. Exp. 2017;65:233&#x2013;240. doi: 10.1007/s00005-016-0427-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-016-0427-5</ArticleId><ArticleId IdType="pmc">PMC5434172</ArticleId><ArticleId IdType="pubmed">27699445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the crispr-cas9 system. Nat. Protoc. 2013;8:2281&#x2013;2308. doi: 10.1038/nprot.2013.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Chung J.H., Kim H.M., Kim D.W., Kim H. Designed nucleases for targeted genome editing. Plant. Biotechnol. J. 2016;14:448&#x2013;462. doi: 10.1111/pbi.12465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pbi.12465</ArticleId><ArticleId IdType="pubmed">26369767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakade S., Yamamoto T., Sakuma T. Cas9, cpf1 and c2c1/2/3-what&#x2019;s next? Bioengineered. 2017;8:265&#x2013;273. doi: 10.1080/21655979.2017.1282018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2017.1282018</ArticleId><ArticleId IdType="pmc">PMC5470521</ArticleId><ArticleId IdType="pubmed">28140746</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Cai D., Wang Z., He Z., Chen S. Development of an efficient genome editing tool in bacillus licheniformis using crispr-cas9 nickase. Appl. Environ. Microbiol. 2018;84:e02608-17. doi: 10.1128/AEM.02608-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.02608-17</ArticleId><ArticleId IdType="pmc">PMC5835740</ArticleId><ArticleId IdType="pubmed">29330178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez A.A., Lim W.A., Qi L.S. Beyond editing: Repurposing crispr-cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 2016;17:5&#x2013;15. doi: 10.1038/nrm.2015.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2015.2</ArticleId><ArticleId IdType="pmc">PMC4922510</ArticleId><ArticleId IdType="pubmed">26670017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson M.M., Himpsl S.D., Mobley H.L.T. Insertional mutagenesis protocol for constructing single or sequential mutations. Methods Mol. Biol. (CliftonN.J.) 2019;2021:61&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">31309496</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676. doi: 10.1016/j.cell.2006.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.024</ArticleId><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Qian K., Du Z., Cao J., Petersen A., Liu H., Blackbourn L.W.T., Huang C.L., Errigo A., Yin Y., et al. Modeling als with ipscs reveals that mutant sod1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:796&#x2013;809. doi: 10.1016/j.stem.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.02.004</ArticleId><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E., Sandoe J., Williams L.A., Boulting G.L., Moccia R., Wainger B.J., Han S., Peng T., Thams S., Mikkilineni S., et al. Pathways disrupted in human als motor neurons identified through genetic correction of mutant sod1. Cell Stem Cell. 2014;14:781&#x2013;795. doi: 10.1016/j.stem.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Chen J., Liu W., Li X., Chen Q., Liu T., Gao S., Deng M. The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the fus-p525l mutation. Neurogenetics. 2015;16:223&#x2013;231. doi: 10.1007/s10048-015-0448-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0448-y</ArticleId><ArticleId IdType="pubmed">25912081</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic als in ipsc-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl. Neurodegener. 2015;4:13. doi: 10.1186/s40035-015-0036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S. Mutant sod1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S., Kato M., Abe Y., Matsumura T., Nishino T., Aoki M., Itoyama Y., Asayama K., Awaya A., Hirano A., et al. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (als): Immunohistochemical studies on sporadic als, superoxide dismutase 1 (sod1)-mutated familial als, and sod1-mutated als animal models. Acta Neuropathol. 2005;110:101&#x2013;112. doi: 10.1007/s00401-005-1019-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1019-3</ArticleId><ArticleId IdType="pubmed">15983830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yi F., Fu L., Yang J., Wang S., Wang Z., Suzuki K., Sun L., Xu X., Yu Y., et al. Crispr/cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient ipscs. Protein Cell. 2017;8:365&#x2013;378. doi: 10.1007/s13238-017-0397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0397-3</ArticleId><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A., Namboori S.C., Zhang X., VanDongen A.M.J., Stanton L.W. Genetic correction of sod1 mutant ipscs reveals erk and jnk activated ap1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Rep. 2017;8:856&#x2013;869. doi: 10.1016/j.stemcr.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Watanabe A., Tsukita K., Woltjen K., Yamamoto T., Hotta A., Kondo T., Kitaoka S., Ohta A., et al. The src/c-abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., et al. Frequency of the c9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gami P., Murray C., Schottlaender L., Bettencourt C., De Pablo Fernandez E., Mudanohwo E., Mizielinska S., Polke J.M., Holton J.L., Isaacs A.M., et al. A 30-unit hexanucleotide repeat expansion in c9orf72 induces pathological lesions with dipeptide-repeat proteins and rna foci, but not tdp-43 inclusions and clinical disease. Acta Neuropathol. 2015;130:599&#x2013;601. doi: 10.1007/s00401-015-1473-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1473-5</ArticleId><ArticleId IdType="pubmed">26347457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The c9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted degradation of sense and antisense c9orf72 rna foci as therapy for als and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T., McAvoy K., Russell K., Wen X., Pang Y., Morris B., Pasinelli P., Trotti D., Haeusler A. Repeat-associated non-aug translation in c9orf72-als/ftd is driven by neuronal excitation and stress. Embo Mol. Med. 2019;11:e9423. doi: 10.15252/emmm.201809423.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809423</ArticleId><ArticleId IdType="pmc">PMC6365928</ArticleId><ArticleId IdType="pubmed">30617154</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S., Stauffer J.E., Jiang J., Garcia S.D., Taylor A.E., Schulte D., Ohkubo T., Schloffman C.L., Maldonado M., Baughn M., et al. Sense-encoded poly-gr dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with tdp-43 in dendrites of repeat-expanded c9orf72 amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:459&#x2013;474. doi: 10.1007/s00401-017-1793-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1793-8</ArticleId><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N., Bieniek K.F., Zhang Y.J., Ross K., Gendron T.F., Murray M.E., Rademakers R., Petrucelli L., Dickson D.W. Poly-gr dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in c9orf72-related brain disease. Acta Neuropathol. Commun. 2018;6:63. doi: 10.1186/s40478-018-0564-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0564-7</ArticleId><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Pribadi M., Yang Z., Kim T.S., Swartz E.W., Huang A.Y., Chen J.A., Dokuru D., Baek J., Gao F., Fua A.T., et al. Crispr-cas9 targeted deletion of the c9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived ips cells. J. bioRxiv. 2016:051193. doi: 10.1101/051193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/051193</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi D.C., Tewari B.P., Singh M., Joshi P.G., Joshi N.B. Ampa receptor activation causes preferential mitochondrial ca2+ load and oxidative stress in motor neurons. Brain Res. 2015;1616:1&#x2013;9. doi: 10.1016/j.brainres.2015.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.04.042</ArticleId><ArticleId IdType="pubmed">25944722</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B.T., Livesey M.R., Zhao C., Gregory J.M., James O.T., Cleary E.M., Chouhan A.K., Gane A.B., Perkins E.M., Dando O., et al. C9orf72 repeat expansion causes vulnerability of motor neurons to ca(2+)-permeable ampa receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A.M., Westeneng H.J., Terpstra M.L., Zundel C.A., Vieira de S&#xe1; R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426&#x2013;438. doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.H., Badders N., Valentine M., Miller B.L., Wong P.C., et al. Ggggcc repeat expansion in c9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133. doi: 10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Yang D., Pribadi M., Kim T.S., Krishnan G., Choi S.Y., Lee S., Coppola G., Gao F.B. Partial inhibition of the overactivated ku80-dependent DNA repair pathway rescues neurodegeneration in c9orf72-als/ftd. Proc. Natl. Acad. Sci. USA. 2019;116:9628&#x2013;9633. doi: 10.1073/pnas.1901313116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901313116</ArticleId><ArticleId IdType="pmc">PMC6511021</ArticleId><ArticleId IdType="pubmed">31019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y., Huang E.J. Mechanisms of fus mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016;1647:65&#x2013;78. doi: 10.1016/j.brainres.2016.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.03.036</ArticleId><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>An H., Skelt L., Notaro A., Highley J.R., Fox A.H., La Bella V., Buchman V.L., Shelkovnikova T.A. Als-linked fus mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 2019;7:7. doi: 10.1186/s40478-019-0658-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0658-x</ArticleId><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Lyashchenko A.K., Lu L., Nasrabady S.E., Elmaleh M., Mendelsohn M., Nemes A., Tapia J.C., Mentis G.Z., Shneider N.A. Als-associated mutant fus induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T., Maragkakis M. Amyotrophic lateral sclerosis associated fus mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 2018;8:15575. doi: 10.1038/s41598-018-33964-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordov&#xe1;s L., Patel A., Welters M., Vanwelden T., et al. Hdac6 inhibition reverses axonal transport defects in motor neurons derived from fus-als patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative stress in als: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Formella I., Svahn A.J., Radford R.A.W., Don E.K., Cole N.J., Hogan A., Lee A., Chung R.S., Morsch M. Real-time visualization of oxidative stress-mediated neurodegeneration of individual spinal motor neurons in vivo. Redox Biol. 2018;19:226&#x2013;234. doi: 10.1016/j.redox.2018.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.08.011</ArticleId><ArticleId IdType="pmc">PMC6126400</ArticleId><ArticleId IdType="pubmed">30193184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Dharmalingam P., Vasquez V., Mitra J., Boldogh I., Rao K.S., Kent T.A., Mitra S., Hegde M.L. Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target? Mech. Ageing Dev. 2017;161:163&#x2013;176. doi: 10.1016/j.mad.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2016.09.005</ArticleId><ArticleId IdType="pmc">PMC5316312</ArticleId><ArticleId IdType="pubmed">27663141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo W., Mitra J., Hegde P.M., Vandoorne T., Eckelmann B.J., Mitra S., Tomkinson A.E., Van Den Bosch L., Hegde M.L. Mutant fus causes DNA ligation defects to inhibit oxidative damage repair in amyotrophic lateral sclerosis. Nat. Commun. 2018;9:3683. doi: 10.1038/s41467-018-06111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06111-6</ArticleId><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M., Pal A., Goswami A., Lojewski X., Japtok J., Vehlow A., Naujock M., G&#xfc;nther R., Jin M., Stanslowsky N., et al. Impaired DNA damage response signaling by fus-nls mutations leads to neurodegeneration and fus aggregate formation. Nat. Commun. 2018;9:335. doi: 10.1038/s41467-017-02299-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02299-1</ArticleId><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Naujock M., Stanslowsky N., Bufler S., Naumann M., Reinhardt P., Sterneckert J., Kefalakes E., Kassebaum C., Bursch F., Lojewski X., et al. 4-aminopyridine induced activity rescues hypoexcitable motor neurons from amyotrophic lateral sclerosis patient-derived induced pluripotent stem cells. Stem Cells (Dayt. Ohio) 2016;34:1563&#x2013;1575. doi: 10.1002/stem.2354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2354</ArticleId><ArticleId IdType="pubmed">26946488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Jiang X., Chen G., Xu J. Interaction of amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with proteins involved in metabolic and protein degradation pathways. Neurobiol. Aging. 2015;36:527&#x2013;535. doi: 10.1016/j.neurobiolaging.2014.07.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.044</ArticleId><ArticleId IdType="pubmed">25192599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. Tdp-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular mechanisms of tdp-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. Tdp-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Tann J.Y., Wong L.W., Sajikumar S., Ib&#xe1;&#xf1;ez C.F. Abnormal tdp-43 function impairs activity-dependent bdnf secretion, synaptic plasticity, and cognitive behavior through altered sortilin splicing. Embo J. 2019;38 doi: 10.15252/embj.2018100989.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100989</ArticleId><ArticleId IdType="pmc">PMC6396160</ArticleId><ArticleId IdType="pubmed">30692134</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In vivo genome editing improves motor function and extends survival in a mouse model of als. Sci. Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Liu Y., Li Z., Ma Y., Zhang G., Liu Y., Bu H., Song X., et al. The deletion of mutant sod1 via crispr/cas9/sgrna prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2019 doi: 10.1038/s41434-019-0116-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-019-0116-1</ArticleId><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F.A., Cong L., Yan W.X., Scott D.A., Gootenberg J.S., Kriz A.J., Zetsche B., Shalem O., Wu X., Makarova K.S., et al. In vivo genome editing using staphylococcus aureus cas9. Nature. 2015;520:186&#x2013;191. doi: 10.1038/nature14299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14299</ArticleId><ArticleId IdType="pmc">PMC4393360</ArticleId><ArticleId IdType="pubmed">25830891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.J. Minimizing off-target effects in crispr-cas9 genome editing. Cell Biol. Toxicol. 2019;35:399&#x2013;401. doi: 10.1007/s10565-019-09486-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10565-019-09486-4</ArticleId><ArticleId IdType="pmc">PMC6883159</ArticleId><ArticleId IdType="pubmed">31317359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Scavuzzo M.A., Chmielowiec J., Sharp R., Bajic A., Borowiak M. Enrichment of g2/m cell cycle phase in human pluripotent stem cells enhances hdr-mediated gene repair with customizable endonucleases. Sci. Rep. 2016;6:21264. doi: 10.1038/srep21264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21264</ArticleId><ArticleId IdType="pmc">PMC4757933</ArticleId><ArticleId IdType="pubmed">26887909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Staahl B.T., Alla R.K., Doudna J.A. Enhanced homology-directed human genome engineering by controlled timing of crispr/cas9 delivery. eLife. 2014;3:e04766. doi: 10.7554/eLife.04766.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.04766</ArticleId><ArticleId IdType="pmc">PMC4383097</ArticleId><ArticleId IdType="pubmed">25497837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu V.T., Weber T., Wefers B., Wurst W., Sander S., Rajewsky K., K&#xfc;hn R. Increasing the efficiency of homology-directed repair for crispr-cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 2015;33:543&#x2013;548. doi: 10.1038/nbt.3198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3198</ArticleId><ArticleId IdType="pubmed">25803306</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Couratier P., Blasco H., Andres C.R., Beltran S., Meininger V., Vourc&#x2019;h P. Genetics of amyotrophic lateral sclerosis. Rev. Neurol. 2017;173:254&#x2013;262. doi: 10.1016/j.neurol.2017.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.030</ArticleId><ArticleId IdType="pubmed">28449881</ArticleId></ArticleIdList></Reference><Reference><Citation>Vildan C., Sule D., Turker B., Hilmi U., Sibel K.B. Genetic alterations of c9orf72, sod1, tardbp, fus, and ubqln2 genes in patients with amyotrophic lateral sclerosis. Cogent Med. 2019;6:1. doi: 10.1080/2331205X.2019.1582400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2331205X.2019.1582400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>